We respond to NICE’s devastating decision to provisionally reject the use of olaparib on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said NICE’s decision to provisionally reject the use of olaparib on the NHS was "devastating".
10 Nov 2022
Breast Cancer Now responds to latest NHSE Cancer Wait Times data, calling for the FDS to be raised to 95%
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, responded to the latest NHS England cancer waiting times data, calling for the Faster Diagnosis Standard to be raised to 95%.
13 Oct 2022
Fantastic outcome for certain patients with incurable secondary triple negative breast cancer as pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) is approved for use on the NHS in Scotland
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said that the approval of pembrolizumab (Keytruda) in combination with chemo for use on the NHS in Scotland was fantastic news.
10 Oct 2022
Pembrolizumab in combination with chemo is approved for use on the NHS in Scotland
Breast Cancer Now hails a fantastic outcome for certain patients with incurable secondary triple negative breast cancer, as pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) is approved for use on the NHS in Scotland.
10 Oct 2022
We welcome approval of palbociclib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said the approval of palbociclib with fulvestrant for routine use on the NHS was absolutely fantastic news for breast cancer patients.
23 Sept 2022
We respond to research about breast cancer surgery margins
22 Sept 2022
We respond to research about physical activity and breast cancer risk
07 Sept 2022
Breast Cancer Now responds to the HSJ and BBC Newsnight's joint special investigation about long cancer waits
11 Aug 2022
We respond to MP Dawn Butler's mission to find the Million Missing Mammograms
02 Aug 2022
Breast Cancer Now welcomes NICE decision to recommend alpelisib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said it was fantastic news that alpelisib with fulvestrant has now been recommended by the National Institute for Health and Care Excellence (NICE) for routine use on the NHS.
14 Jul 2022
Breast Cancer Now celebrates landmark victory as Trodelvy is recommended for use on the NHS in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, has expressed her excitement that Trodelvy has finally been recommended by the National Institute for Health and Care Excellence (NICE) for use on the NHS in England.
14 Jul 2022
We respond to the approval of breast cancer drug abemaciclib for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, expressed his excitement about the approval of breast cancer drug abemaciclib for routine use on the NHS.
17 Jun 2022